UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
AMENDMENT NO. 2
FORM F-3
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
NYMOX PHARMACEUTICAL CORPORATION |
(Exact name of registrant as specified in its charter) |
Bahamas |
| The NASDAQ Stock Market, LLC (NASDAQ Capital Market) |
(State or other jurisdiction of incorporation or organization) |
| (Name of each exchange on which each stock it to be registered) |
Bay & Deveaux Streets
Nassau, The Bahamas
(Address of principal executive offices)
Contact person: Erik Danielsen
Tel. (800) 936-9669; email: edanielsen@nymox.com, fax: (514) 332-2227
Copy to:
Cutler Law Group, P.C.
6575 West Loop South, Suite 500
Bellaire, Texas 77401
Tel. (713) 888-0040; email: rcutler@cutlerlaw.com; fax (713)583-7150
From time to time after the effective date of this Registration Statement
(Approximate date of commencement of proposed sale to the public)
This Amendment No. 2 is filed only to provide an updated opinion of legal counsel pursuant to oral comments from the United States Securities and Exchange Commission.
Exhibits and Financial Statement Schedules
Exhibit |
| Description of Exhibit |
| Incorporated by Reference or Attached Hereto |
| ||||
|
| Attached hereto. | ||
|
| Previously filed | ||
| Consent of Thayer O’Neal and Company LLC, Independent Registered Public Accounting Firm |
| Previously filed. |
2 |
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant named below certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form F-3 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Nassau, Bahamas, on this 5th day of May 2020.
| NYMOX PHARMACUETICALS INC. |
| |
| |||
| By: | /s/ DR. PAUL AVERBACK |
|
| Dr. Paul Averback |
| |
| Chief Executive Officer and President |
|
Pursuant to the requirements of the Securities Act, this registration statement has been signed by the following persons in the capacities and on the dates indicated.
Signature |
| Title |
| Date |
| ||||
/s/ Dr. Paul Averback |
| |||
Dr. Paul Averback |
| Chief Executive Officer, President and Director |
| May 5, 2020 |
| ||||
/s/ Erik Danielsen |
| |||
Erik Danielsen |
| Chief Financial Officer and Controller |
| May 5, 2020 |
| ||||
/s/ Randall Lanham |
| |||
Randall Lanham |
| General Counsel, Secretary and Director |
| May 5, 2020 |
| ||||
/s/ James G. Robinson |
| |||
James G. Robinson |
| Director |
| May 5, 2020 |
| ||||
/s/ Prof. David Morse |
| |||
Prof. David Morse |
| Director |
| May 5, 2020 |
| ||||
/s/ M. Richard Cutler |
| |||
M. Richard Cutler |
| Director |
| May 5, 2020 |
3 |